Immune Therapeutics, Inc.

IMUN · OTC
Analyze with AI
6/30/2024
3/31/2024
12/31/2023
9/30/2023
Assets
Cash & Equivalents-$0$5
Short-Term Investments$0$0
Receivables$0$0
Inventory$0$0
Other Curr. Assets$0$0
Total Curr. Assets-$0$5
Property Plant & Equip (Net)$0$0
Goodwill$0$0
Intangibles$0$722
Long-Term Investments$0$0
Tax Assets$0$0
Other NC Assets$6$6
Total NC Assets$6$727
Other Assets$0$0
Total Assets$5$732
Liabilities
Payables$1,256$1,350
Short-Term Debt$1,170$1,119
Tax Payable$0$0
Deferred Revenue$0-$1,741,324
Other Curr. Liab.$1,627$1,743,067
Total Curr. Liab.$5,308$4,212
LT Debt$0$0
Deferred Rev, NC$0$0
Deferred Tax Liab, NC$0$0
Other NC Liab.$0$0
Total NC Liab.$0$0
Other Liabilities$0$0
Cap. Leases$0$0
Total Liabilities$5,308$4,212
Equity
Pref Stock$0$0
Common Stock$8$8
Retained Earnings-$386,112-$384,278
AOCI$0$0
Other Equity$380,801$380,789
Total Equity-$5,303-$3,480
Supplemental Information
Minority Interest$0$0
Total Liab. & Tot. Equity$5$732
Net Debt$1,170$0$0$1,114
Immune Therapeutics, Inc. (IMUN) Financial Statements & Key Stats | AlphaPilot